GlassScriptPhysician profile
Kent J Stock
NPI 1356331904
$7,645.27
in general payments reported to CMS, 2019-2025
32 companies · $862 in 2025
The $862 reported for 2025 was more than what 77% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $996 · 2020: $969 · 2021: $1,091 · 2022: $1,147 · 2023: $1,394 · 2024: $1,186 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,202 · Education: $202 · Consulting Fee: $37.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,202.18 |
| Education | $201.88 |
| Consulting Fee | $37.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $1,458.87 | 2019-2025 | Arikayce, Brinsupri |
| Gilead Sciences, INC. | $963.91 | 2019-2025 | |
| Viiv Healthcare Company | $763.23 | 2019-2025 | Cabenuva, Rukobia, Dovato |
| Merck Sharp & Dohme LLC | $740.22 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Astellas Pharma US INC | $638.21 | 2019-2025 | Cresemba |
| Abbvie INC. | $568.64 | 2019-2025 | Avycaz, Teflaro |
| Melinta Therapeutics, LLC | $426.89 | 2019-2025 | Rezzayo, Kimyrsa, Vabomere |
| Shionogi INC | $358.71 | 2021-2025 | Fetroja |
| Theratechnologies INC. | $286.41 | 2019-2023 | Egrifta, Trogarzo |
| Paratek Pharmaceuticals, INC. | $278.56 | 2019-2025 | Nuzyra |
| Allergan, INC. | $195.24 | 2019-2020 | |
| Janssen Biotech, INC. | $182.24 | 2019-2022 | |
| La Jolla Pharmaceutical Company | $121.58 | 2021-2025 | Xacduro |
| Cipla USA INC. | $104.72 | 2021 | |
| Ferring Pharmaceuticals INC. | $72.47 | 2023-2025 | Rebyota |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $63.36 | 2019-2020 | |
| Adma Biomanufacturing LLC | $61.14 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $60.43 | 2020-2022 | |
| Pfizer INC. | $59.87 | 2023-2025 | |
| Napo Pharmaceuticals INC | $49.59 | 2019 | |
| Nabriva Therapeutics, Plc | $47.18 | 2020-2021 | |
| Grifols USA, LLC | $37.05 | 2019-2023 | Gamunex-C |
| Janssen Pharmaceuticals, INC | $34.28 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $31.23 | 2024-2025 | Vibativ |
| Dynavax Technologies Corporation | $15.55 | 2019 | |
| Aimmune Therapeutics, INC. | $14.60 | 2025 | Vowst |
| Vyera Pharmaceuticals, LLC | $11.09 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Stock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.